Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal Medicine By China’s Tasly First TCM In Western Trials

This article was originally published in PharmAsia News

Executive Summary

Traditional Chinese medicine appears to be gaining greater acceptance in the Western, although there is widespread agreement on a need for standardization. China's Tasly Pharmaceutical has submitted an herbal drug, danshen, already available in much of Africa for treating a variety of diseases, is undergoing clinical trials in the European Union and in the United States where the FDA approved it as the first TCM for testing. The lack of scientific proof for the effectiveness of herbal treatments, some used in other countries for hundreds of years, has stymied their acceptance by Western drug makers and nations. U.S. and Chinese agree globalization will come only after TCM compounds are subjected to standardization. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel